PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Novel drugs for hypertension and heart failure: struggling for a place under the sun.

Abstract Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits but has also some limitations. LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two recently developed novel agents for the management of these conditions.
PMID
Related Publications

Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.

Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.

Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.

Authors

Mayor MeshTerms
Keywords

LCZ696

albuminuria

diabetic kidney disease

finerenone

heart failure

hypertension

mineralocorticoid receptor antagonists

neprilysin

Journal Title current pharmaceutical design
Publication Year Start




PMID- 28176630
OWN - NLM
STAT- Publisher
DA  - 20170208
LR  - 20170208
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
DP  - 2017 Feb 06
TI  - Novel drugs for hypertension and heart failure: struggling for a place under the 
      sun.
LID - 10.2174/1381612823666170206154706 [doi]
AB  - BACKGOUND: Current drug therapy for the management of arterial hypertension and
      heart failure has provided substantial benefits but has also some limitations.
      LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and
      finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two
      recently developed novel agents for the management of these conditions. METHODS: 
      This review aims to present the pathophysiological basis for the use of these two
      novel drugs, critically discuss available clinical data, and provide future
      perspectives. RESULTS: LCZ696 seems a very promising antihypertensive agent, that
      additionally generates clinically meaningful benefits in patients with heart
      failure with reduced injection fraction and raises expectations for the
      management of patients with heart failure with preserved ejection fraction.
      Finerenone aims to be safer than current aldosterone antagonists and has been so 
      far tested in patients with heart failure and in patients with albuminuria. First
      available data are very promising for the efficacy of the drug, while it provides
      a better safety profile than current mineralocorticoid antagonists. CONCLUSION:
      LCZ696 and finerenone are two novel drugs for the management of arterial
      hypertension and heart failure. First available data point toward important
      clinical benefits from their use. Future large trials further investigating the
      cardiovascular profile of these agents will establish the use of these drugs.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at
      [email protected]
FAU - Faselis, Charles
AU  - Faselis C
AD  - VA Medical Center 50 Irving Street, NW Washington, DC 20422,. United States.
FAU - Boutari, Chrysoula
AU  - Boutari C
FAU - Doumas, Michael
AU  - Doumas M
FAU - Imprialos, Konstantinos
AU  - Imprialos K
FAU - Stavropoulos, Konstantinos
AU  - Stavropoulos K
FAU - Kokkinos, Peter
AU  - Kokkinos P
LA  - eng
PT  - Journal Article
DEP - 20170206
PL  - Netherlands
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
OTO - NOTNLM
OT  - LCZ696
OT  - albuminuria
OT  - diabetic kidney disease
OT  - finerenone
OT  - heart failure
OT  - hypertension
OT  - mineralocorticoid receptor antagonists
OT  - neprilysin
EDAT- 2017/02/09 06:00
MHDA- 2017/02/09 06:00
CRDT- 2017/02/09 06:00
PHST- 2016/12/13 [received]
PHST- 2017/01/19 [revised]
PHST- 2017/01/31 [accepted]
AID - CPD-EPUB-81551 [pii]
AID - 10.2174/1381612823666170206154706 [doi]
PST - aheadofprint
SO  - Curr Pharm Des. 2017 Feb 6. doi: 10.2174/1381612823666170206154706.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>